Sodium Fluoride for Otosclerosis: A Systematic Review and Meta‐analysis
Otolaryngology–Head and Neck Surgery · 06.11.2026
DOI: 10.1002/ohn.70508 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 06.11.2026. Verfasst von Jonathan M Hughes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Sodium fluoride has historically been used to slow progression of hearing loss in patients with otosclerosis, yet the contemporary clinical benefit and optimal daily dose remain unclear. We performed a systematic review and meta‐analysis to evaluate audiologic outcomes associated with fluoride therapy. Data Sources PubMed, Scopus, CINAHL, and Cochrane were searched from inception through July 23, 2025. Review Methods Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines were followed. Randomized and observational studies reporting pre‐treatment and post‐treatment hearing outcomes in patients with otosclerosis treated with sodium fluoride were included. Outcome measures included continuous variables (means), proportions (%), and relative risks (RRs) with 95% confidence intervals.
Results
A total of 10 studies comprising 2352 patients were included. Pooled all‐dose analysis showed that fluoride was associated with superior hearing stabilization (RR 1.6; 95% CI, 1.0‐2.5) and reduced deterioration (RR 0.2; 95% CI, 0.2‐0.3) compared with controls. Hearing improvement or stabilization occurred in 96.4% (95% CI, 90.7%‐99.4%) receiving high‐dose fluoride, 83.8% (95% CI, 57.4‐98.6%) receiving low‐dose fluoride, and 57.2% (95% CI, 30.7%‐81.7%) of untreated controls. Patients not receiving fluoride therapy, including placebo controls, experienced deterioration at a rate of 27.1% (95% CI, 2.3%‐65.4%).
Conclusion
For patients with otosclerosis, high‐dose fluoride was associated with a protective effect against hearing loss, and low‐dose therapy was associated with stabilization. Patients not receiving fluoride experienced higher rates of hearing loss and lower rates of stabilization. Despite modest evidence quality and variable audiologic definitions, findings support selective use in patients for whom medical management is preferred.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
- Philadelphia College of Osteopathic Medicine, Suwanee, Georgia, USA.
- Wayne State University School of Medicine, Detroit, Michigan, USA.
ORCID-Profile: Shaun A Nguyen
Zitieren
APA
Hughes, J. M., Gandra, N., Nguyen, S. A., Meyer, T. A., & Labadie, R. F. (2026). Sodium Fluoride for Otosclerosis: A Systematic Review and Meta‐analysis. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70508
Vancouver
Hughes JM, Gandra N, Nguyen SA, Meyer TA, Labadie RF. Sodium Fluoride for Otosclerosis: A Systematic Review and Meta‐analysis. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70508
BibTeX
@article{Hughes2026,
author = {Hughes, Jonathan M and Gandra, Neeti and Nguyen, Shaun A and Meyer, Ted A and Labadie, Robert F},
title = {Sodium Fluoride for Otosclerosis: A Systematic Review and Meta‐analysis},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
doi = {10.1002/ohn.70508}
}
EUVIMED